Delivery Order SPE2DB22D3004-SPE2DB25FRX97
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,632.54 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Mounjaro 10 mg/0.5 ml pen (tirzepatide injection), a diabetes and weight management medication. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award through open competition. The contract is to be completed by August 26, 2025, with performance based in Conshohocken, Pennsylvania, where AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,170.98 to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 12.5 mg/0.5 mL pen injections on August 29, 2025, with completion scheduled for September 2, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through the federal procurement process. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a $60,990.95 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Mounjaro 10 mg/0.5 mL pens (tirzepatide), a diabetes treatment medication. This firm fixed-price delivery order, with an ultimate completion date of September 17, 2025, represents a non-competitive award under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The place of performance is located in Conshohocken,...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Mounjaro 5mg/0.5ml (tirzepatide), a GLP-1 receptor agonist commonly used for diabetes management. This competitively awarded, firm fixed-price delivery order has a ceiling value of $5,441.80 and is scheduled for completion by September 24, 2025. The contract carries no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to...
- The Defense Logistics Agency awarded a $5,245.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 5 mg/0.5 mL pen injectors on September 17, 2025, with an ultimate completion date of September 18, 2025. The order is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and represents a single transaction within AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $4,645.08 to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 10 mg/0.5 mL pens on July 22, 2025, with completion scheduled for July 23, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed-price pricing and represents a single delivery order for the diabetes medication to support federal healthcare needs. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $4,081.35 to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 15 mg/0.5 mL pens on September 10, 2025. This firm fixed price delivery order, with an ultimate completion date of September 11, 2025, represents a competitively awarded contract with no set-aside designation. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office and serves as...
- The Defense Logistics Agency awarded a $2,448.81 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 2.5 mg/0.5 mL pen injectors on August 15, 2025, with an ultimate completion date of August 18, 2025. This non-set-aside contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a pediatric or lower-dose formulation of the diabetes medication tirzepatide, which supports the federal...
- The Defense Logistics Agency awarded a $12,551.88 firm fixed price delivery order to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 5 mg/0.5 ml pen injectors on September 16, 2025, with completion scheduled for September 17, 2025. This non-competitive delivery order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's pharmaceutical supply role within the federal medical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $11,125.48 to AmerisourceBergen Drug Corp for Mounjaro 5 mg/0.5 mL pens (tirzepatide injection), a diabetes medication, with completion targeted for September 15, 2025. This competitive, firm fixed-price delivery order represents a non-set-aside award to the pharmaceutical distributor's corporate office location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FRX97Delivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,176.72 for Mounjaro 5 mg/0.5 ml pen (tirzepatide injection), a GLP-1 receptor agonist used for diabetes management. This firm fixed-price delivery order, awarded on August 11, 2025, with ultimate completion by August 12, 2025, was competitively awarded with no set-aside designation. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This comprehensive prime vendor contract enables the company to supply pharmaceuticals and medical supplies supporting military healthcare programs globally, serving organizations including the Defense Health Agency and U.S. Coast Guard. AmerisourceBergen's consistent receipt of competitive delivery orders across diverse therapeutic domains demonstrates its established capability as a critical pharmaceutical distributor within the federal medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 8/11/25 |